Synthesis, characterization, crystal structure, DNA and BSA binding, molecular docking and in vitro anticancer activities of a mononuclear dioxido-uranium(VI) complex derived from a tridentate ONO aroylhydrazone

Spectroscopic and molecular modeling studies of binding interaction between the new complex of yttrium and 1,10-phenanthroline derivatives with DNA and BSA

In this study, the 4,9 diazafluoren-9-one ligand and [Y(Daf)2Cl3.OH2] complex were synthesized. The interaction of this complex with DNA and bovine serum albumin (BSA) was investigated by UV-vis and fluorescence spectroscopy. The molecular docking method was used to confirm the experimental results, investigate the type of interaction, and determine the binding site. The binding constant and Stern-Volmer constant were calculated using spectroscopy techniques. The binding constant of the Y-complex with DNA and BSA obtained using the UV-vis technique was 1.61 × 105 M-1 and 0.49 × 105 M-1, while that obtained using the fluorescence method was 3.39 × 105 M-1 and 3.63 × 105 M-1, respectively. The results of experimental and theoretical data showed that the interaction between the yttrium complex and DNA and BSA is driven by the hydrogen bond and van der Waals interaction, respectively. The yttrium complex communicates with DNA via the groove interaction. This complex has high binding energy with bovine serum albumin. In addition, the molecular docking results showed that the complex binds to the IIA subdomain of BSA (site I). Finally, anticancer activity of the yttrium complex was studied on MCF-7 and A549 cell lines by using the MTT method. The IC50 values obtained showed that the yttrium complex possesses anticancer activity.

Probing the interaction of uranyl(VI) complex with bovine serum albumin via in-depth experimental and computational perspectives

Interaction aspects of uranyl(VI) complexes as well as the coordinated ONNO-donor ligand with bovine serum albumin (BSA) were investigated by the fluorescence spectroscopy and computational insights. Under optimal physiological condition, it was observed that there was significant decrease in fluorescence intensity of BSA upon interaction with uranyl(VI) complexes as well as the ligand. The mechanism of interaction between the uranyl(VI) complex and BSA protein was examined by fluorescence measurement. The Stern-Volmer constant, binding affinity, binding constant, standard free energy, and fluorescence lifetime decay profile of BSA in the absence as well as in the presence of uranyl(VI) complex were determined. Furthermore, the conformational binding of uranyl(VI) complexes with BSA protein was explored via molecular docking studies, and confirmed that there is a strong affinity between the Trp-213 residue in the binding pocket of sub-domain IIA and uranyl(VI) complex.

Synthesis, Structural Investigations, Molecular Docking, and Anticancer Activity of Some Novel Schiff Bases and Their Uranyl Complexes

Three novel 2-aminopyrazine Schiff bases derived from salicylaldehyde derivatives and their uranyl complexes were synthesized and characterized by elemental analysis, UV-vis, FTIR, molar conductance, and thermal gravimetric analysis (TGA). The proposed structures were optimized using density functional theory (DFT/B3LYP) and 6-311G ∗(d,p) basis sets. All uranyl complexes are soluble in DMSO and have low molar conductance, which indicates that all the complexes are nonelectrolytes. The DNA binding of those Schiff bases and their uranyl complexes was studied using UV-vis spectroscopy, and screening of their ability to bind to calf thymus DNA (CT-DNA) showed that the complexes interact with CT-DNA through an intercalation mode, for which the K_b values ranged from 1 × 10⁶ to 3.33 × 10⁵ M^-1. The anticancer activities of the Schiff base ligands and their uranyl complexes against two ovarian (Ovcar-3) and melanoma cell lines (M14) were investigated, and the results indicated that uranyl complexes exhibit better results than the Schiff base ligands. Molecular docking identified the distance, energy account, type, and position of links contributing to the interactions between these complexes and two different cancer proteins (3W2S and 2OPZ).